T reatments designed to favorably affect the clinical impact of coronary artery disease (CAD) have two fundamental goals. The first goal is to diminish the symptomatic limitations imposed by arterial obstructive disease, in which the vessel's capacity to fully meet the varying oxygen demands of the myocardium is impaired. Vascular capacity may be abnormal because of a fixed flow-limiting coronary stenosis,12 abnormal epicardial vessel tone,3,4 intermittent arterial vasospasm,5 microvascular dysfunction,6'7 or inadequate collateral development. A variety of medical approaches are now used to palliate symptoms by favorably altering the oxygen supply-demand imbalance. Alternatively, this first goal of symptom relief may be achieved through more direct structural and/or physiological changes that favorably affect the diminished vascular flow capacity. These include relaxation of excess vasoconstrictor tone, development of collateral vessels, or reduction in the severity of flow-limiting stenosis ("regression"). The latter has been questioned as a possible mechanism for symptom relief. In this report, the data supporting the occurrence of regression and its mechanisms are reviewed, together with the role of lipid lowering in achieving it.
The second fundamental goal of therapy in CAD is to prevent the anticipated worsening of symptoms or progression to a clinical event such as sudden death, myocardial infarction, or worsening angina requiring bypass surgery or angioplasty. In this report, the mechanisms of gradually progressive arterial obstruction are discussed together with the mechanisms of plaque disruption resulting in abrupt worsening of arterial obstruction. Data presented indicate a linkage between lipid lowering and stabilization of the plaque structure. This set of observations supports the hypothesis that lipid-lowering therapy prevents clinical events by selectively depleting of lipids, or "regressing," a relatively small subgroup of lipid-rich plaques that are predisposed to plaque fissuring, ulceration, and hemorrhage and that account for the great majority of clinical events.
Promoting Regression Our understanding of atherosclerosis regression comes largely from animal experiments and from human arteriographic studies. There are important biological differences between the various experimental models of atherosclerosis and the disease in humans, and there are important differences in the methods for assessing disease. As a result, concepts emerging from these two perspectives are not always comparable. Even the basic term regression means something quite different to the experimental pathologist than to the clinician, as can be seen in the histological sections of Figure 1 . To the former, regression means shrinkage of intimal plaque through a reduction in its major components: smooth muscle, macrophages, connective tissues, and lipid. To the clinician interpreting human disease in terms of its arteriographic appearance, regression is defined as an increase in the diameter of the narrowed arterial lumen; such improvement occurs infrequently in the natural course of the disease. This "luminal" definition of regression encompasses the effects of plaque shrinkage but also of a variety of other possible mechanisms. For Table 2 , are surprisingly consistent. Each study demonstrated a benefit from treatment, whether by diet, by diet supplemented by other lifestyle changes, or by lipid-altering drugs. As a generalization of the composite of results, 8% of the control group patients were judged to have improvement in arterial obstruction ("regression") during the study period. By contrast, about one fourth of treated patients were found to have improved (a threefold increase). An example of this type of comparison, using FATS results, is provided in Figure 2 . As seen in Table  2 , averaged estimates of disease severity per patient worsened (progressed) by about 3% stenosis among the control subjects, whereas they improved (regressed) by 1-2% stenosis among the treated patients.
When these results are expressed in terms of absolute change in arterial narrowing, they appear to be remarkably small. In FATS, for example, the minimum lumen diameter of control group lesions progressively narrowed by a per-patient average of -0.050 mm over 2.5 years, whereas treated group lesions improved by +0.024 (p<0.01), for a treatment-induced difference of 0.074 mm (less than 0.1 mm!). Similarly, this difference was 0.096 mm (p<0.01) in SCRIP, 0.13 mm (p<0.05) in Heidelberg, and 0.35 mm (p<0.003) in STARS. These treatment effects achieve statistical significance because the group variance of this estimate of disease change is also quite small-a testament to the precision of the QCA methods. In nearly every study, the frequency of clinical cardiovascular events was reduced substantially, although the reductions achieved statistical significance in only three. Failure to confirm a clinical benefit is not unexpected, since the sample size required for trials using arteriographic end points is much smaller than for trials using clinical end points. Figure 3 provides examples of regression occurring in intensively treated FATS patients over a 2.5 -year period. As these images suggest and the data of Figure 4 confirm, regression may occur in mild, moderate, and severe lesions. Although regression was more likely to occur among the more severe lesions, the relative benefit from therapy was roughly uniform over the spectrum of disease severity. Those 25 The composite of such evidence from randomized arteriographic trials is summarized in Table 2 . Again, despite the diversity of these trials, the evidence for reduced lesion progression is surprisingly consistent. Approximately one half of the control group patients in Table 2 were judged to have worsening arterial obstruction during the study period. By contrast, about one fourth of the treated patients worsened (a 50% reduction from control values). Again, the example of Figure 2 illustrates this comparison, using FATS data.33 Figure 4 demonstrates that the likelihood of a lesion's progression is, in part, determined by its baseline severity. Intensive lipid-lowering therapy decreases, by about fourfold, the likelihood of definite lesion progression among mild and moderate lesions but does not appear to reduce the chance of progression of the small number of severe lesions studied.
Preventing Plaque Disruption and Clinical Events Prevention of Clinical Events
The landmark Lipid Research Clinics-Coronary Primary Prevention Trial68 established that significant reduction of clinical coronary events but not of cardiac or total mortality occurred in association with a 9% reduction, relative to the dietary control, in total cholesterol and a 13% reduction in LDL cholesterol achieved with diet and cholestyramine. Importantly, the magnitude of cardiovascular benefit correlated in a subgroup analysis with the degree of total and of LDL cholesterol reduction. 68 The Helsinki Heart Trial69 also achieved a significant reduction in total cardiac events but not mortality. And the 15-year follow-up of the Coronary Drug project showed highly significant (11%) reductions in cardiac and all-cause mortality only in the niacintreated group. 70 Additional evidence that clinical events are decreased by lipid-lowering therapy is presented in Figure  5 . One can imagine the pathogenesis of each of these arteriographic examples in terms of the histological section in Figure 1B . Figure 5A shows a hemorrhagic pocket in the atheroma connected to the lumen by a narrow-necked fissure, or vent. In such cases, it has long been debated whether increased internal pressure in the plaque (caused by bleeding or by an inflammatory abscess) has burst the fibrous cap into the lumen or whether a primary fissure in the plaque permits bleeding into the core region. Figures 5B and 6 are almost certainly examples of hemorrhage into the plaque via an upstream fissure from the lumen, with resultant expan- sion of the plaque and obstruction of flow when the fibrous cap is driven into the lumen. Figure 5C shows an angiographic finding commonly called "ulceration" of the plaque. It Figure  1A ) into one that is much more susceptible to fissuring ( Figure 1B ). Prevention of Plaque Disruption
As described above, plaque fissuring is predicted by certain lipid-related aspects of plaque morphology including macrophage foam cell density, core lipid pool size, and possible cytotoxicity from oxidized LDL. Reduction of plasma LDL might be expected to reduce the likelihood of fissuring because of the experimentally demonstrated favorable effects of LDL reduction on these predictors. As a consequence, the frequency of abrupt progression to clinical events should decline among patients in whom LDL has been therapeutically reduced. Indeed, this has been the case. Analysis of 13 coronary events among 146 FATS patients reveals that the events were associated with a culprit coronary lesion in the distribution of worsening ischemia that progressed significantly in severity from the baseline stenosis measurement to that at the time of the event. As seen in Figure 7, -rl. -r1---I-r--r-rA-1
